EditorialEditorial

M. Bayer

Clin Osteol 2010; 15(4): 135

Cinacalcet hydrochloride - current therapeutic useReview articles

J. Lazarová

Clin Osteol 2010; 15(4): 136-141

Cinacalcet hydrochloride represents a major breakthrough in the treatment ofboth primary and secondary hyperparathyroidism. This review aims to summarize current knowledge on cinacalcet hydrochloride therapeutic indications and use.

Potential new and less frequent indications of cinacalcetReview articles

F. Švára

Clin Osteol 2010; 15(4): 144-147

Throughout six years of the clinical use of cinacalcet, numerous articles have been published, describing cinacalcet therapy in situati­ ons outside indications stated in the summary of product characteristics (SPC). Not only in the Czech Republic, such use of a drug is possible. However, it should be supported by either sufficient literature evidence and/or current scientific knowledge. In such cases, the physician or health care facility take full responsibility for potential adverse effects of the drug. In the case of cinacalcet from the group of calcimimetics, the most common indications outside the approved SPC are secondary hyperparathyroidism...

Calcium in the treatment of metabolic bone diseaseGuidelines

P. Fojtík, P. Novosad

Clin Osteol 2010; 15(4): 149-154

Calcium plays, as well as vitamine D, very important role in prevention of osteopenia and osteoporesis and its treatment. Sufficient absorption of calcium depends on its daily content in alimentation, which may differ significantly. The various kinds of aliments are very different, as far as the calcium content concerns. It is recommendable to be acquainted with the factors influencing the calcium absorbtion, the content of preparates we usually substitute, a sorbtion of calcium.

ESR, CALCR and VDR gene polymorphisms and their relation to bone mineral density, bone turnover markers and incidence of fractures in Slovak osteoporotic womenReview articles

D. Galbavý, R. Omelka, M. Bauerová, O. Hunák

Clin Osteol 2010; 15(4): 156-164

Osteoporosis is a disease characterised by reduced bone mineral density (BMD) and microarchitectural deterioration of bone tissue with an increased fracture risk. Genetic factors play an important role in the pathogenesis of osteoporosis. The estrogen receptor (ESR), vitamin D receptor (VDR) and calcitonin receptor (CALCR) are proteins which mediate hormonal action in target tissues. Bone re­ sorption and formation are caused by hormones through their receptors on osteoblasts and osteoclasts. Therefore, possible variability in the ESR, VDR and CALCR genes could play a role in variability of BMD followed by variability in fracture risk. The purpose...

Recommended procedure for diagnosing and treatment of postmenopausal osteoporosis II. AddendumInformations

J. Rosa

Clin Osteol 2010; 15(4): 165-168

News from around the worldLiterature

Clin Osteol 2010; 15(4): 169-172

Congress AnnouncementsInformations

Clin Osteol 2010; 15(4): 173

Zápis z jednání výboru SMOS dne 9. září 2010 v BratislavěInformations

Clin Osteol 2010; 15(4): 174